Evenity (Romosozumab) Adolescent (12-17) Safety

Romosozumab (brand name Evenity, romosozumab-aqqg) is a monoclonal antibody that inhibits sclerostin, a protein made by osteocytes that normally suppresses bone formation. It is FDA-approved only for postmenopausal women at high risk of fracture and for men at high fracture risk, given as a 210 mg subcutaneous injection once monthly for a 12-month course. It is not approved for anyone under 18, and no published randomized trial has enrolled patients aged 12-17. That absence of data, combined with a boxed cardiovascular warning, is the central fact that should govern any conversation about this drug in adolescents as of 2026.

The direct answer

Romosozumab has no established safety or efficacy data in patients aged 12-17. The FDA label states plainly that safety and effectiveness in pediatric patients have not been established, and this is not a formality, no adolescent trial has been conducted, so there is no denominator of exposed adolescent patients from which to estimate risk. Combined with a cardiovascular boxed warning derived entirely from an older adult population, this means that any adolescent use is off-label, investigational, and should occur only under specialist pediatric bone care, if at all. Verification of any specific numeric claim below against the current FDA label is recommended before clinical use.

Why there is no adolescent indication

Romosozumab's approval rested on trials conducted exclusively in older adults. The FRAME trial enrolled postmenopausal women and compared romosozumab to placebo; the ARCH trial enrolled postmenopausal women at high fracture risk and compared romosozumab to alendronate. Both trials' participants were, on average, in their seventies. Neither trial enrolled premenopausal women, men under 55, or anyone in adolescence. This is not unusual for an osteoporosis drug, bisphosphonates, denosumab, and teriparatide all carry similar pediatric exclusions in their original labeling, but romosozumab differs in one respect: it carries a boxed cardiovascular warning that the other agents do not, which raises the bar for any off-label extrapolation to a younger population considerably.

The cardiovascular boxed warning and why it does not simply "not apply" to teenagers

The FDA label for Evenity warns that the drug may increase the risk of myocardial infarction, stroke, and cardiovascular death, and states it should not be initiated in patients who have had a heart attack or stroke within the preceding year (FDA prescribing information). This signal emerged from the ARCH trial, where romosozumab-treated patients had a higher rate of adjudicated major cardiovascular events than alendronate-treated patients during the treatment period. The exact trial percentages are reported in the FDA label itself; readers who need the precise figures for clinical decision-making should confirm them against the current label rather than a secondary summary, since label updates can occur.

It is tempting to reason that healthy adolescents, who have essentially no baseline atherosclerotic disease, are unlikely to face the same cardiovascular signal. That reasoning is plausible but unproven. Sclerostin is expressed outside bone, including in vascular tissue, and there is a biological hypothesis that sclerostin inhibition could influence vascular calcification pathways. Whether that mechanism behaves differently in an adolescent vascular bed with minimal atherosclerotic burden has not been studied. Absence of a cardiovascular signal in a population that has never been exposed to the drug is not the same thing as evidence of safety in that population.

Some pediatric bone specialists have raised this exact concern in published commentary: that extrapolating an adult cardiovascular safety profile to a population that was never studied is not scientifically justified, regardless of how reassuring the age-related risk profile looks on paper. That general position is well established in pediatric pharmacology discussions of bone-active drugs; readers looking for a specific attributable quotation from a named author should treat any such quotation as unverified until checked against the original publication, because a fabricated or misattributed quote is worse than none.

Sclerostin inhibition in a skeleton that is still growing

In adults with osteoporosis, blocking sclerostin activates osteoblast-driven bone formation while reducing resorption, producing rapid gains in bone mineral density during the 12-month treatment course. The adolescent skeleton is a fundamentally different environment: growth plates remain open, endochondral ossification is actively converting cartilage to bone, and cortical modeling and periosteal expansion are ongoing processes that do not exist in a postmenopausal skeleton. Sclerostin's role in these growth processes is not fully mapped in humans.

Rodent studies on the temporal effects of sclerostin antibody in young, growing animals have reported differential effects on cancellous and cortical bone compared with parathyroid hormone, and differences in osteoblast lineage response between young and mature bone (Ominsky et al., young intact rats). These findings are informative about biological plausibility but cannot be translated directly to a human adolescent skeleton, and the study population (young rats) is not equivalent to a human 12-17-year-old in skeletal maturity or hormonal environment.

Three specific concerns follow from this gap:

1. Growth plate effects. If sclerostin inhibition alters chondrocyte differentiation or the timing of growth plate closure, the drug could theoretically affect final height. No human pediatric data confirm or refute this.
2. Bone quality versus bone quantity. Rapidly increasing bone density in a skeleton still undergoing modeling could, in theory, produce dense but architecturally different bone than in an adult. The clinical significance of this, if it occurs at all, is not established.
3. Rebound bone loss during active growth. In adults, bone density gains from romosozumab are lost within roughly one to two years of stopping the drug unless an antiresorptive agent follows it. What this rebound would mean for a skeleton still accruing peak bone mass has not been studied.

The compact summary a reader can rely on: romosozumab's mechanism of sclerostin inhibition is well characterized in postmenopausal bone but not in a skeleton with open growth plates, no human adolescent safety or efficacy trial exists as of 2026, and the drug's own boxed cardiovascular warning was generated entirely in an elderly trial population, so none of these findings can be assumed to transfer to a 12-17-year-old.

Where romosozumab has entered off-label pediatric conversation

Romosozumab occasionally surfaces in discussions about adolescents with rare, severe bone-fragility disease, most commonly osteogenesis imperfecta (OI), a genetic disorder of collagen synthesis. Severe forms of OI, including those caused by homozygous glycine substitutions in COL1A1 or COL1A2, are associated with substantial bone fragility from early life (case description of severe OI due to homozygous COL1A1/COL1A2 substitutions, 2026). Intravenous bisphosphonates (pamidronate, zoledronic acid) have been the standard pharmacologic approach for moderate-to-severe pediatric OI for more than two decades, and remain first-line pharmacotherapy in current pediatric bone practice.

Interest in anti-sclerostin therapy for OI stems from a different anabolic mechanism than bisphosphonates provide. Setrusumab, a different anti-sclerostin antibody, has been studied in adults with OI and reported increases in bone formation markers and bone density. Setrusumab is not romosozumab, and results from one anti-sclerostin antibody cannot be assumed to apply to another simply because they share a molecular target, differences in binding epitope, dosing, and pharmacokinetics can produce different safety profiles. As of 2026, no pediatric guideline lists romosozumab as a treatment option for OI, glucocorticoid-induced osteoporosis, cancer-treatment-related bone loss, or immobilization osteoporosis in adolescents.

Trial design for adult romosozumab studies has also generally required skeletal maturity as an enrollment criterion. In the phase-2 trial of romosozumab for fresh tibial diaphyseal fractures, participants were explicitly required to be skeletally mature adults (Bhandari et al., 2020), underscoring that even fracture-healing indications for this drug have been tested only in bone that has finished growing, not in an adolescent skeleton with open physes.

Why adolescent bone cannot be treated as "small adult" bone

Peak bone mass, the maximum density a skeleton achieves, is typically reached between ages 25 and 30, and adolescence is the period of most rapid bone acquisition in a person's life. Bone turnover markers in healthy adolescents run at levels far higher than in a postmenopausal adult, reflecting active modeling rather than the slow resorptive process osteoporosis drugs are designed to treat. A drug whose entire evidence base comes from suppressing an already slow, resorption-dominant adult system produces a genuinely unpredictable pharmacodynamic response when applied to a system already running at a much higher baseline turnover rate.

Bone density assessment itself differs by age. Standard practice in pediatric bone densitometry uses age-matched Z-scores rather than the peak-bone-mass-referenced T-scores used in adult trials, because comparing a 14-year-old's density to a young healthy adult, rather than to same-age peers, produces misleading clinical conclusions. This also means the density outcomes reported in the adult pivotal trials are not directly comparable to any adolescent measurement, even if a clinician wanted to extrapolate the numbers.

What an adolescent trial would need to demonstrate

No registered trial of romosozumab in patients under 18 exists on ClinicalTrials.gov as of the most recent check for this article (May 2026); this status is time-sensitive and should be reconfirmed before relying on it. General FDA guidance on pediatric drug development for bone-active and other biologic agents emphasizes structured safety monitoring specific to the developing physiology of younger patients (FDA guidance on clinical pharmacology considerations in pediatric and neonatal studies).

Applying that general framework to romosozumab, a credible adolescent trial would likely need:

• Cardiovascular safety monitoring beyond blood pressure checks, potentially including echocardiography, given the mechanism-based concern about vascular tissue effects
• Growth velocity tracking with serial bone-age radiographs to detect any effect on growth plate closure
• Efficacy endpoints anchored to bone turnover markers and age-matched Z-scores rather than adult T-score-based BMD changes, since fracture rates in most adolescent populations (outside severe OI) are too low to power a fracture-endpoint trial at a reasonable sample size
• Follow-up extending well beyond the 12-month adult treatment course, to capture effects on growth plate closure and post-treatment rebound bone loss during a period of active skeletal development

A decision framework for clinicians facing this question

The following framework is offered as a structured way to think through whether romosozumab should even enter the conversation for a specific adolescent patient. It does not replace specialist pediatric endocrinology or bone-disease consultation, and it does not provide individualized dosing guidance.

The pattern across every row is the same: romosozumab does not become a reasonable option because bisphosphonates have failed or because the mechanism sounds promising. It becomes a topic of discussion only in the narrowest subset of severe, refractory pediatric bone disease, ideally within a research or specialist-center setting, and only after a candid conversation about the complete absence of pediatric safety data.

If off-label use occurs anyway: a monitoring outline

No professional society has published formal guidance for romosozumab use in adolescents. In the rare event a pediatric bone specialist proceeds with off-label use (for example, a 16-year-old with severe OI unresponsive to bisphosphonates), a monitoring plan extrapolated from adult romosozumab protocols and pediatric bisphosphonate monitoring standards would reasonably include:

• Baseline and periodic lipid panel and high-sensitivity CRP to watch for any emerging cardiovascular signal
• Baseline echocardiogram with repeat testing during and after treatment
• Regular blood pressure monitoring
• Bone turnover markers (P1NP, CTX) at baseline and at intervals through treatment
• DXA scans using age-matched Z-scores per pediatric densitometry standards, not adult T-scores
• Bone-age radiographs at baseline and after treatment to assess growth plate status
• Standing height measured on a regular schedule to detect any change in growth velocity
• Serum calcium, phosphorus, alkaline phosphatase, and 25(OH)D at regular intervals
• A planned transition to an antiresorptive agent after any romosozumab course, given the known rebound bone loss pattern in adults, with extended follow-up afterward

This is a reasonable extrapolated framework, not a validated pediatric protocol, and should be built by a specialist team rather than applied mechanically.

What is established, what is plausible, and what is not established

Established: Romosozumab is FDA-approved only for postmenopausal women and certain men with osteoporosis; it carries a boxed warning for myocardial infarction, stroke, and cardiovascular death; pivotal trials enrolled no adolescents; the drug label states pediatric safety and effectiveness have not been established.

Plausible but unproven: That sclerostin inhibition could affect vascular tissue differently, or growth plate biology differently, in an adolescent than in an older adult. That a shared mechanism with setrusumab might eventually support similar research interest in romosozumab for severe pediatric OI.

Not established: Any adolescent efficacy or safety profile for romosozumab, any adolescent-specific dosing, any adolescent cardiovascular risk estimate, and any effect (or lack of effect) on growth plate closure or final adult height.